Tinengotinib shows activity in FGFR-altered cholangiocarcinoma post-FGFR inhibitor therapy. Learn more about the phase 2 ...
Neurizon Therapeutics Ltd has received FDA clearance for its lead candidate, NUZ-001, to enter the HEALEY ALS Platform Trial ...
A prediction model for response to immune checkpoint inhibition in advanced melanoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback